Article
GHK-Cu on Skin: What Studies in People Found, and What They Did Not
A copper-binding peptide with decades of laboratory research and only a few small trials in people
In this article
Key takeaways
GHK-Cu is a copper-binding peptide found in human blood and used in skin products. In people, one 1994 trial found more diabetic ulcer closure with a GHK-Cu gel, and a 13-patient trial after laser resurfacing found no objective skin benefit; most other evidence comes from cells and animals.
- Evidence available
- A mix of human, animal and laboratory studies
- Confidence
- Low Two small controlled human trials with different outcomes, decades apart; most supporting work is laboratory or animal research summarized in reviews by the peptide's discoverer.
- Main limitation
- The only positive human trial is from 1994 and has not been confirmed by a published trial checked for this page.

U.S. regulatory status
- GHK-Cu
Not FDA-approved
Not the active ingredient of any FDA-approved drug (Drugs@FDA search, 2026-10-18). FDA lists GHK-Cu for injectable routes among bulk drug substances that may present significant safety risks in compounding.
Source 5, verified
GHK-Cu is a small peptide, three amino acids long, that binds copper and is found in human blood, saliva and urine 1. It is widely used in skin and hair products 2, but the evidence from people is thin. A randomized trial published in 1994 found that more of the ulcer area closed in diabetic foot ulcers treated with a GHK-Cu gel than with an inactive gel 4. A small randomized trial after laser skin resurfacing found no measurable difference in redness, wrinkles or overall skin quality; only the patients’ own ratings favored GHK-Cu 3. Most other claims about GHK-Cu come from cell and animal studies. It is not the active ingredient of any FDA-approved drug.
Where GHK-Cu comes from
GHK is named for its three amino acids: glycine, histidine and lysine. Loren Pickart isolated it in 1973 as an activity in human albumin that made liver tissue from older people produce proteins the way younger tissue does; it was later identified as this tripeptide, which binds copper tightly 1. Its level in blood plasma falls by more than half between age 20 and age 60 1,2.
Two reviews by Pickart and coauthors, from 2015 and 2018, summarize most of the research described on this page 1,2. Both draw mainly on laboratory and animal work.
What the controlled studies in people found
Diabetic foot ulcers. In a multicenter, randomized, placebo-controlled trial with blinded evaluators, people with diabetic neuropathic ulcers on the sole of the foot received standardized wound care plus either a GHK-Cu gel or an inactive gel 4. The median ulcer area that closed was 98.5 percent with GHK-Cu and 60.8 percent with the inactive gel, and the authors report that closure was three times faster 4. Infections were less common in ulcers treated with GHK-Cu right after debridement, the removal of dead tissue (7 percent against 34 percent) 4. The abstract does not state how many patients took part.
Skin after CO2 laser resurfacing. In a 2006 trial, patients who had laser resurfacing around the mouth were randomized to skin-care products with or without GHK-Cu 3. Thirteen patients completed it. Computer analysis and blinded evaluators found no significant difference between the groups in how quickly redness resolved, and no difference in wrinkles or overall skin quality; both groups improved 3. Patients using GHK-Cu rated their improvement in skin quality higher on a questionnaire 3. A study this small can miss a real effect, but it does not show one. The earlier version of this page said this study found reduced redness; it did not.
Cosmetic creams. The 2015 review describes a 12-week study of a GHK-Cu facial cream in 71 women and a 12-week study of an eye cream in 41 women, with improvements in fine lines and skin density 1. The review cites both to presentations from 2002, one of them at an American Academy of Dermatology meeting, rather than to full journal papers 1, so their methods could not be checked for this page.
A randomized trial registered in 2026, called CuHeal, is testing a GHK-Cu gel on standardized small wounds in an estimated 60 healthy adults, with one wound on each person treated with GHK-Cu and the other with an inactive gel. It was still recruiting on October 18, 2026 6.
What comes only from cells and animals
In laboratory experiments, GHK-Cu at very low concentrations stimulated both the making and the breakdown of collagen and glycosaminoglycans, components of the tissue that supports skin 1. In rats, rabbits, mice and pigs it improved measures of wound healing 1,2. These results show what the molecule can do in a dish or an animal. They do not show what a cream does on human skin.
The often-repeated figure of more than 4,000 human genes comes from the Broad Institute’s Connectivity Map, a database of gene-activity profiles measured in five cancer cell lines exposed to 1,309 compounds 1. The 2018 review reports that GHK changed the activity of 31.2 percent of the genes examined by at least half 2. A change in gene activity in cultured cancer cells is not a measured outcome in people.
FDA status
GHK-Cu is not the active ingredient of any FDA-approved drug (Drugs@FDA search, October 18, 2026). FDA lists GHK-Cu for injectable use among bulk drug substances for compounding that may present significant safety risks: the agency says compounded injectable GHK-Cu may provoke an immune reaction because the peptide can clump and carry impurities, and that there are limited human data on its safety 5. The nomination that had placed it in that category was later withdrawn 5. FDA has announced that its Pharmacy Compounding Advisory Committee will discuss GHK-Cu and four other substances at a meeting before the end of February 2027 7. This page does not cover how cosmetic products are regulated.
Sources
7 sources. Numbers in the text link to the entry they cite.
- 1.
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration
Pickart L, Vasquez-Soltero JM, Margolina A. Biomed Res Int. 2015.
Review PMID 26236730 DOI 10.1155/2015/648108Checked October 18, 2026
Cited for: GHK in plasma, saliva and urine; about 200 ng/mL at age 20 and 80 ng/mL by age 60; isolated by Pickart in 1973 as an activity in human albumin; collagen and glycosaminoglycan synthesis and breakdown at 1-10 nM; wound healing in rats, mice and pigs; 'at least 4,000 genes'; Connectivity Map profiles from five cancer cell lines and 1,309 small molecules; facial cream (71 women) and eye cream (41 women) studies cited to 2002 meeting proceedings
Back to text (a)Back to text (b)Back to text (c)Back to text (d)Back to text (e)Back to text (f)Back to text (g)Back to text (h)Back to text (i)
- 2.
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Pickart L, Margolina A. Int J Mol Sci. 2018.
Review PMID 29986520 DOI 10.3390/ijms19071987Checked October 18, 2026
Cited for: Widely used in skin and hair products; plasma level 200 ng/mL at 20, 80 ng/mL at 60; 31.2% of genes changed by 50% or more; animal wound studies in rabbits and rats
Back to text (a)Back to text (b)Back to text (c)Back to text (d)Back to text (e)
- 3.
Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
Miller TR, Wagner JD, Baack BR, et al. Arch Facial Plast Surg. 2006.
Randomized controlled trial PMID 16847171 DOI 10.1001/archfaci.8.4.252Checked October 18, 2026
Cited for: Randomized; 13 completed; no significant between-group difference in erythema resolution (computer analysis and blinded evaluators); no between-group difference in wrinkles or overall skin quality; questionnaire favored GHK-Cu (P = .04)
Back to text (a)Back to text (b)Back to text (c)Back to text (d)
- 4.
Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper
Mulder GD, Patt LM, Sanders L, et al. Wound Repair Regen. 1994.
Randomized controlled trial PMID 17147644 DOI 10.1046/j.1524-475X.1994.20406.xChecked October 18, 2026
Cited for: Multicenter, randomized, evaluator-blinded, placebo-controlled; diabetic neuropathic plantar ulcers; median closure 98.5% vs 60.8% (vehicle); closure three times faster; infection 7% vs 34% when started immediately after debridement
Back to text (a)Back to text (b)Back to text (c)Back to text (d)
- 5.
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026)
U.S. Food and Drug Administration. fda.gov. 2026.
Regulatory documentfda.govChecked October 18, 2026
Cited for: GHK-Cu (for injectable routes) listed among substances previously in category 2 whose nominations were withdrawn; risk of immunogenicity from aggregation and peptide-related impurities; limited human data
- 6.
Topical GHK-Cu Gel for Acute Skin Wound Healing (CuHeal)
Hudson Biotech. ClinicalTrials.gov. 2026.
Trial registrationNCT07437586Checked October 18, 2026
Cited for: Phase 2, randomized, quadruple-masked, vehicle-controlled split-wound study; 60 healthy adults (estimated); recruiting; start 2026-02-02
- 7.
Meeting of the Pharmacy Compounding Advisory Committee (early announcement; content current as of 04/15/2026)
U.S. Food and Drug Administration. fda.gov. 2026.
Regulatory documentfda.govChecked October 18, 2026
Cited for: PCAC meeting before the end of February 2027 to discuss LL-37, GHK-Cu, dihexa acetate, Melanotan II and PEG-MGF for the 503A bulks list
